3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Transitional Cell
13
Urinary Bladder Neoplasms
12
Ureteral Neoplasms
4
Neoplasm Metastasis
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Carcinoma, Renal Cell
2
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Melanoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Advanced Bladder Cancer
1
Interventions
pembrolizumab
5
fludarabine
2
enfortumab vedotin
2
darolutamide
2
atezolizumab
2
aldesleukin
2
Riluzole
2
Nivolumab
2
Mitomycin
2
Fecal Microbiota Transplantation
2
Cyclophosphamide
2
vedolizumab
1
relatlimab
1
prednylidene
1
olaparib
1
lenvatinib
1
deltacortene
1
cabozantinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tadalafil
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Rivaroxaban
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Prednisone
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Neoplasms
×
enfortumab vedotin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT06724159
2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
500 enrolled